68Ga-戊柔抑素PET/CT改善被脑与眼外肌生理性18F-FDG摄取掩盖的颞骨复发性骨髓瘤检出
71岁女性多发性骨髓瘤患者,基线18F-FDG与68Ga-pentixafor PET/CT均示骨髓弥漫性摄取增高,9周期化疗后达非常好的部分缓解,伊沙佐米维持期间进展。随访PET/CT中,68Ga-pentixafor PET/CT额外检出右侧颞骨新发溶骨性破坏病灶,该病灶在18F-FDG PET/CT中因脑与眼外肌强烈生理性摄取而 initially 漏诊。
要点
- 68Ga-pentixafor PET/CT可检出被脑和眼外肌生理性18F-FDG摄取掩盖的颞骨骨髓瘤病灶。
- 多发性骨髓瘤随访中,18F-FDG PET/CT对颅骨区域病灶可能因生理性摄取而漏诊。
- 68Ga-pentixafor PET/CT在多发性骨髓瘤再分期中可能提供额外病灶信息。
核心结论
- 68Ga-pentixafor PET/CT额外检出右侧颞骨新发溶骨性破坏病灶,该病灶在18F-FDG PET/CT中因脑与眼外肌强烈生理性摄取而 initially 漏诊。
研究设计与样本
- 个案报道:1例71岁女性多发性骨髓瘤患者,接受基线及随访18F-FDG与68Ga-pentixafor PET/CT。
主要发现
- 基线18F-FDG与68Ga-pentixafor PET/CT均示骨髓弥漫性摄取增高,符合骨髓瘤浸润。
- 9周期化疗后达非常好的部分缓解;伊沙佐米维持期间出现疾病进展。
- 随访PET/CT示骨髓弥漫性浸润病变,68Ga-pentixafor PET/CT额外检出右侧颞骨新发溶骨性破坏病灶,18F-FDG PET/CT initially 漏诊。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A 71-year-old woman was recently diagnosed with multiple myeloma. Baseline 18F-FDG and 68Ga-pentixafor PET/CT showed diffusely increased uptake in bone marrow, consistent with infiltrated myeloma. She had very good partial response after 9 cycles of chemotherapy. However, during the maintenance with ixazomib, she experienced progressed disease. In the follow-up PET/CT, except for diffusely infiltrated disease in bone marrow, 68Ga-pentixafor PET/CT additionally detected a new emerging lesion in the right temporal bone with lytic bone destruction, which was initially missed in 18F-FDG PET/CT due to the intense physiological uptake of the brain and extraocular muscles.
引用
- Pan Q, Luo Y, Cao X, et al. 68Ga-Pentixafor PET/CT Improves the Detection of Recurrent Myeloma in the Temporal Bone Masked by the Physiological 18F-FDG Uptake of the Brain and Extraocular Muscles. Clin Nucl Med. 2022. PMID: 35020649. doi:10.1097/RLU.0000000000003979
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。